ATE511854T1 - Systeme und verfahren zum öffnen von obstruierten biologischen kanälen - Google Patents

Systeme und verfahren zum öffnen von obstruierten biologischen kanälen

Info

Publication number
ATE511854T1
ATE511854T1 AT07008805T AT07008805T ATE511854T1 AT E511854 T1 ATE511854 T1 AT E511854T1 AT 07008805 T AT07008805 T AT 07008805T AT 07008805 T AT07008805 T AT 07008805T AT E511854 T1 ATE511854 T1 AT E511854T1
Authority
AT
Austria
Prior art keywords
conduit
obstruction
methods
systems
enzyme
Prior art date
Application number
AT07008805T
Other languages
German (de)
English (en)
Inventor
Nicholas Franano
Original Assignee
Proteon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteon Therapeutics Inc filed Critical Proteon Therapeutics Inc
Application granted granted Critical
Publication of ATE511854T1 publication Critical patent/ATE511854T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Processing Of Meat And Fish (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
AT07008805T 1999-09-24 2000-09-24 Systeme und verfahren zum öffnen von obstruierten biologischen kanälen ATE511854T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15593899P 1999-09-24 1999-09-24

Publications (1)

Publication Number Publication Date
ATE511854T1 true ATE511854T1 (de) 2011-06-15

Family

ID=22557384

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07008805T ATE511854T1 (de) 1999-09-24 2000-09-24 Systeme und verfahren zum öffnen von obstruierten biologischen kanälen
AT00965396T ATE361095T1 (de) 1999-09-24 2000-09-24 Verwendung von elastase zur öffnung verstopfter arterien und venen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00965396T ATE361095T1 (de) 1999-09-24 2000-09-24 Verwendung von elastase zur öffnung verstopfter arterien und venen

Country Status (11)

Country Link
EP (4) EP1220830B1 (https=)
JP (2) JP5763286B2 (https=)
AT (2) ATE511854T1 (https=)
AU (1) AU7612100A (https=)
CA (1) CA2385488C (https=)
CY (3) CY1106656T1 (https=)
DE (1) DE60034694T2 (https=)
DK (3) DK1220830T3 (https=)
ES (3) ES2534938T3 (https=)
PT (3) PT1220830E (https=)
WO (1) WO2001021574A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063838B1 (en) 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
AU2004213050B2 (en) * 2003-02-20 2010-09-09 Proteon Therapeutics, Inc. Methods for the treatment and prevention of diseases of biological conduits
BRPI0515569A (pt) * 2004-09-22 2008-07-29 Proteon Therapeutics Inc métodos para reduzir vasospasmo em um segmento de um conduto biológico, para reduzir a capacidade de um vaso sofrer vasospasmo em um segmento de um conduto biológico e para reduzir o acúmulo de hiperplasia ìntima em um segmento de um conduto biológico
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
CA2861033C (en) 2012-01-12 2017-07-25 Auxilium International Holdings, Inc. Clostridium histolyticum enzymes and methods for the use thereof
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
ES3036011T3 (en) 2017-03-01 2025-09-11 Endo Operations Ltd Apparatus and method for assessing and treating cellulite
KR20240001279A (ko) 2017-03-28 2024-01-03 엔도 벤쳐즈 리미티드 개선된 콜라게나제 생성 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489261A (en) * 1981-01-26 1996-02-06 Trustees Of Boston University Hydrogels capable of supporting cell growth
US4636195A (en) * 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
US4803294A (en) * 1987-10-29 1989-02-07 G. D. Searle & Co. Process and intermediates for the preparation of halogenated protease inhibitors
JPH0286777A (ja) * 1988-09-22 1990-03-27 Sankyo Co Ltd サル膵臓エラスターゼｉ
HK1003981A1 (en) * 1989-01-27 1998-11-13 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
NL8900943A (nl) * 1989-04-14 1990-11-01 Euro Biopharm Technology B V Protease inhibitor.
US5318531A (en) * 1991-06-11 1994-06-07 Cordis Corporation Infusion balloon catheter
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5422261A (en) * 1993-04-16 1995-06-06 Baxter International Inc. Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
US5409926A (en) 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
ES2281898T3 (es) * 1994-12-13 2007-10-01 Human Genome Sciences, Inc. Inhibidor tisular humano de metaloproteinasa-4.
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US5834449A (en) * 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors

Also Published As

Publication number Publication date
JP5763286B2 (ja) 2015-08-12
DK2363142T3 (en) 2015-04-20
AU7612100A (en) 2001-04-24
EP2363142A1 (en) 2011-09-07
EP1923068B1 (en) 2011-06-08
CY1106656T1 (el) 2012-01-25
JP2003523319A (ja) 2003-08-05
WO2001021574A1 (en) 2001-03-29
EP2363142B1 (en) 2015-03-25
EP1220830B1 (en) 2007-05-02
DK1220830T3 (da) 2007-07-16
EP2363142B8 (en) 2015-06-10
EP2332568A1 (en) 2011-06-15
JP5793461B2 (ja) 2015-10-14
ATE361095T1 (de) 2007-05-15
JP2012131830A (ja) 2012-07-12
DE60034694T2 (de) 2008-01-17
EP1220830A1 (en) 2002-07-10
CA2385488A1 (en) 2001-03-29
ES2284528T3 (es) 2007-11-16
PT1923068E (pt) 2011-07-29
ES2364191T3 (es) 2011-08-26
EP1923068A1 (en) 2008-05-21
PT1220830E (pt) 2007-06-11
PT2363142E (pt) 2015-08-04
CY1117932T1 (el) 2017-05-17
CY1112329T1 (el) 2015-12-09
ES2534938T3 (es) 2015-04-30
DE60034694D1 (de) 2007-06-14
WO2001021574A9 (en) 2002-12-27
EP1220830A4 (en) 2005-03-30
DK1923068T3 (da) 2011-06-27
HK1162302A1 (en) 2012-08-31
CA2385488C (en) 2015-07-07
EP2363142A9 (en) 2011-10-19

Similar Documents

Publication Publication Date Title
CY1117932T1 (el) Ελασταση για διανοιξη αποφραγμενων βιολογικων διαυλων
WO1998049972A3 (en) Differential treatment of prosthetic devices
DE59502653D1 (de) Verfahren und vorrichtung zum zusammenführen wenigstens zweier fliessfähigen medien
BR0210718A (pt) Método para o tratamento de material celulósico, e, tecido
ATE431166T1 (de) System zum transfer von flüssigkeit im innenohr und zur diagnose
BR9812171A (pt) Dispositivo cirúrgico de corte endoscópico, e, para a remoção de tecido de uma cavidade de corpo
EP0754072A4 (en) DEVICE FOR LOCALIZED DELIVERY OF A MEDICINAL PRODUCT AND METHODS OF USING SAME
CY1109695T1 (el) Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
DK0944302T3 (da) Anordning til forhindring af et dyrs overskridelse af en områdegrænse
FR2841137B1 (fr) Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement
TR199900310T2 (xx) Trombin inhibit�rleri
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
BR0215389A (pt) Agente preventivo ou terapêutico para distúrbio urinário, método para prevenir ou tratar distúrbio urinário, uso de um composto, composto, pró-droga, processo para preparar o composto, medicamento, e, método para triar um composto
ES2103871T3 (es) Medicamento para oftalmologia y su empleo.
ATE339602T1 (de) Vorrichtung zur katalytischen behandlung eines gasstromes
FR2760199B1 (fr) Dispositif de separation de deux zones a ambiances differentes
DE60235408D1 (de) Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden
ES2103482T3 (es) Antigeno de linfocitos t citotoxicos utilizado como inhibidor de la cisteina proteasa.
EP1325974A3 (en) Seal for pressurized equipments through which the material to be treated is conveyed
SE9700913L (sv) Anordning och förfarande för behandling av innerytan hos en behållare
GB9809555D0 (en) Use of neuropeptide Y receptor agonists for treating migraine
WO2003028537A3 (en) Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
WO2003007800A8 (en) Methods for diagnosing and treating diseases and conditions of the digestive system and cancer
EP1166824A3 (en) Discharge valve for discharge of extinguishing fluid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1923068

Country of ref document: EP